Following the successful Terveystalo cooperation, Nightingale is now increasing its commercial sample volumes with its healthcare partners in Singapore and the US. The company's pilot phase customerships are also in general expected to progress, and we believe the company is actively negotiating new partnerships as well. However, we are now particularly looking for signs of strong growth in commercial sample volumes, which would substantially reduce estimate risks.

Nightingale is just launching the commercial phases with its second and third healthcare partners. The company's comments on the sales pipeline are also promising, and we believe it will announce at least one significant partnership during the current year.

Driven by the Terveystalo partnership, which was successfully launched at the beginning of 2024, revenue is on an upward trend compared to the previous year.